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We report on a patient with long-standing severe autonomic failure that affected his
sympathetic and parasympathetic nervous systems. Antibodies against the ganglionic
acetylcholine receptors were detected in the serum. Removal of the antibodies by
 
means of plasma exchange resulted in a dramatic clinical improvement.
 
e is a pink complexioned person, except when he has stood
 
for a long time, when he may get pale and faint. His handshake is warm
and dry. . . . He is thin because his appetite is modest; he never feels
hunger pains and his stomach never rumbles. . . . As old age comes on he will suffer
from retention of urine and impotence but frequency, precipitancy, and strangury will
not worry him.” Paton’s description of the “hexamethonium man”
 
1
 
 illustrates the con-
sequences of a pharmacologic blockade of ganglionic transmission. Hexamethonium
blocks ganglionic nicotinic acetylcholine receptors, resulting in dysfunction of the ef-
ferent sympathetic and parasympathetic pathways. Disruption of these pathways causes
severe orthostatic hypotension, anhydrosis, decreased production of saliva and tears,
impaired bladder emptying, and erectile dysfunction. Patients with severe autonomic
neuropathy have similar symptoms. Autonomic neuropathy can result from diabetes
mellitus or amyloidosis, but in many patients no cause is evident. Occasional reports
that intravenous immunoglobulins can be effective in autonomic neuropathy
 
2-5
 
 sug-
gest an immune-mediated mechanism.
 
6
 
 The serum of some patients with subacute au-
tonomic neuropathy contains autoantibodies against the ganglionic acetylcholine re-
ceptor,
 
7
 
 and autonomic dysfunction develops in rabbits that are immunized against
the ganglionic acetylcholine receptor.
 
8
 
 These findings suggest that autoimmune auto-
nomic neuropathy is an antibody-mediated neurologic disorder. However, a causal re-
lation between anti–ganglionic acetylcholine receptor antibodies and autonomic failure
has not been convincingly demonstrated in humans.
A 43-year-old man presented with recurrent orthostatic syncope. His symptoms had
developed gradually over a 20-year period. Recently, he was unable to stand upright for
more than a few seconds before fainting. He also reported decreased sweating, dry
mouth, and urinary retention. He had difficulty focusing on near objects. Early satiety,
summary
“
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painful abdominal distention, and severe constipa-
tion had resulted in weight loss. A partial small-
bowel resection performed for suspected bowel
obstruction was not beneficial. Surgery for retro-
grade ejaculations also failed to alleviate his symp-
toms. There was no history of an acute illness pre-
ceding this disorder, and there was no family
history of autonomic dysfunction. Known second-
ary causes of autonomic failure had been ruled out.
On physical examination he weighed 55 kg (with a
body-mass index, defined as the weight in kilo-
grams divided by the square of the height in meters,
of 18.5) and had warm, dry skin. His pupils were
dilated and unresponsive to light. The abdomen was
painfully distended with sparse bowel sounds and
a tympanic percussive sound. Imaging studies
showed a grotesquely dilated ascending and trans-
verse colon that had displaced the liver to the far
left abdomen, with the stomach wedged between
liver and spleen. Gastrointestinal passage, as deter-
mined by the ingestion of radiopaque pellets, was
profoundly delayed.
 
antibody detection
 
Serum samples for antibody studies were collect-
ed before, during, and after treatment. Antibodies
binding to neuronal ganglionic acetylcholine recep-
tors were detected by a radioimmunoprecipitation
assay.
 
9
 
 This assay uses a solubilized acetylcholine
receptor from a human neuroblastoma cell line
(IMR-32) that is labeled with a high-affinity radio-
ligand, 
 
125
 
I-labeled epibatidine. The antigen-bind-
ing capacity of serum is expressed in nanomoles of
 
125
 
I-epibatidine–receptor complexes precipitated
per liter of serum. The upper limit of the normal
range in serum is 0.05 nmol per liter.
 
plasma exchange and immunosuppression
 
Three liters of plasma was removed during each
session through an 11-French double-lumen cath-
eter with the use of a hollow-fiber plasma filter
(PF 1000 N, Gambro). We replaced the removed
plasma with 2.5 liters of 5 percent human albumin
and 0.5 liter of fresh-frozen plasma. Because of re-
lapses, the patient underwent repeated courses of
plasma exchange. Each treatment consisted of plas-
ma exchange on four consecutive days. After the
second relapse, we started treatment with prednis-
olone (at a dose of 60 mg per day) and azathioprine
(at a dose of 100 mg per day). Over time, the doses
were reduced to 5 mg of prednisolone per day and
50 mg of azathioprine per day.
 
autonomic function testing
 
Arterial blood pressure was measured continuously
with the use of a radial-artery catheter. The heart rate
was monitored with the use of electrocardiograms
(Hewlett–Packard). The respiratory sinus arrhyth-
mia ratio was determined as the ratio between the
shortest and longest RR intervals during deep
breathing paced at 6 Hz. For the Valsalva maneuver,
the patient exhaled forcibly into a manometer,
maintaining a pressure of 40 mm Hg for 15 sec-
onds. For the handgrip test, the patient squeezed a
rubber ball with 30 percent of his maximal volun-
tary force. During the cold pressor test, the patient’s
right hand was immersed in a 1:1 mixture of ice
and water for one minute. We assessed saliva pro-
duction by measuring the increase in the weight of
cotton swabs that were placed in the patient’s
mouth for five minutes.
 
10
 
 To assess orthostatic
hypotension, the patient rested supine for at least
10 minutes, then stood and remained motionless
until symptoms occurred. Microneurography at the
peroneal nerve was performed as previously de-
scribed.
 
11
 
pharmacologic testing and baroreflex 
sensitivity
 
While monitoring arterial pressure, we infused in-
cremental bolus doses of intravenous phenyleph-
rine or nitroprusside until a change in the systolic
blood pressure of 25 mm Hg occurred.
 
12
 
 Barore-
flex sensitivity was determined as the slope of the
regression line of changes in blood pressure and
corresponding changes in RR intervals.
 
confocal fluorescence microscopy
 
IMR-32 cells express neuronal ganglionic acetylcho-
line receptors. These cells were cultivated in 80 per-
cent RPMI 1640 medium supplemented with 20 per-
cent fetal-calf serum in chamber slides (Nunc). For
measurements of intracellular calcium, cells were
incubated with 5 µM acetoxymethyl ester for 15 min-
utes at 37°C, followed by two rinses and an addi-
tional incubation for 10 minutes. Measurements
were performed on a confocal microscope (Fluo-
View, Perkin-Elmer) with 488 nm excitation-collect-
ing emission at 525 nm every second. We deter-
mined the intracellular calcium response of 0.1 µM
acetylcholine in the presence and absence of serum
with a known antibody concentration.
methods
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We tested the effect of the patient’s antibodies on
cholinergic responses of IMR-32 cells in vitro. The
addition of 0.1 µM acetylcholine induced a rapid in-
crease in the level of intracellular calcium in these
cells (Fig. 1). This response was attenuated when se-
rum containing 0.001 ng of anti–ganglionic acetyl-
choline receptor antibodies per milliliter was added
to the cells, and it was virtually abolished with the
addition of serum containing 0.1 ng of the anti-
bodies per milliliter. Incubation of the cells with
serum obtained from a normal control subject pro-
duced no change in the intracellular calcium re-
sponse to acetylcholine.
Figure 2 depicts concentrations of anti–gangli-
onic acetylcholine receptor antibody and orthostat-
ic hypotension over 12 months and four courses of
plasma exchange. The antibody concentrations were
directly correlated with decreases in orthostatic
blood pressure (r
 
2
 
=0.41, P<0.001 for systolic blood
pressure; and r
 
2
 
=0.51, P<0.001 for diastolic blood
pressure) and correlated inversely with increases in
orthostatic heart rate (r
 
2
 
=0.33, P=0.002). The mean
concentration of anti–ganglionic acetylcholine re-
ceptor antibody before the plasma exchange was
0.54±0.02 nmol per liter (10 times the upper limit
of the normal range), a value consistent with auto-
immune autonomic neuropathy.
 
9,13
 
 
During the course of the plasma exchange, the
antibody concentrations decreased progressively
to values within the normal range (0.25±0.03,
0.12±0.02, 0.05±0.01, and 0.03±0.01 nmol per li-
ter after days 1, 2, 3, and 4, respectively). With de-
creasing antibody concentrations, the orthostatic
hypotension was markedly reduced and the ortho-
static heart rate increased. After the third day of
plasma exchange, the patient noticed improved or-
thostatic tolerance and had some return of sweat-
ing. After the fourth day, the symptoms had resolved
completely. Dryness of the mouth and eyes im-
proved, as did urinary hesitancy. Ejaculation became
antegrade. The day after the last plasma exchange,
the patient noticed “rumbling” in his abdomen, and
the gastric distention and abdominal pain subse-
quently were relieved.
Before the plasma exchange, the heart rate did
not change with deep breathing or during the Val-
salva maneuver. The blood pressure decreased pro-
foundly during phase II of the Valsalva maneuver.
During phase IV, the pressure overshoot was absent.
The handgrip test and the cold pressor test did not
elicit a pressor response. Blood pressure was 137/72
mm Hg in the supine position and 40/20 mm Hg
after standing for 30 seconds (Fig. 3A). While the
patient was supine, the norepinephrine plasma con-
results
 
Figure 1. Effects of Autoantibodies on Intracellular 
Calcium Responses.
 
Panel A shows cells from a human neuroblastoma cell 
line (IMR-32) before (left) and after (right) the addition 
of 0.1 µM acetylcholine in the presence or absence of a 
known antibody concentration. Panel B shows the typi-
cal course of the concentration of intracellular calcium 
after the addition of acetylcholine in a single cell. The ad-
dition of the antibodies attenuated the intracellular calci-
um response to acetylcholine in a concentration-
dependent manner.
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centration was very low (0.23 nmol per liter [38.9 pg
per milliliter]). The patient was very sensitive to
pharmacologically induced changes in blood pres-
sure. The dose of phenylephrine that increased sys-
tolic blood pressure by 25 mm Hg was 28 µg. The
dose of sodium nitroprusside that decreased blood
pressure by 25 mm Hg was 0.2 µg per kilogram of
body weight. Pharmacologically induced changes
in blood pressure did not elicit an adequate com-
pensatory baroreflex-mediated heart-rate response.
The baroreflex slope was 0 msec per millimeter of
mercury. Saliva production was low (0.25 g within
five minutes). No muscle sympathetic-nerve activity
was recorded at the peroneal nerve.
One week after the plasma exchange, the pa-
tient’s blood pressure was 132/68 mm Hg in the
supine position and 119/64 mm Hg after one min-
ute standing (Fig. 3B). The heart rate increased ap-
propriately, and the patient was able to stand up-
right for more than 15 minutes without symptoms.
The supine norepinephrine concentration had in-
creased by a factor of three (0.76 nmol per liter
[128.7 pg per milliliter]). Responses to the Valsalva
maneuver were normal after the plasma exchange.
Also after the plasma exchange, isometric hand-
grip elicited an increase in blood pressure of 20/17
mm Hg. The respiratory sinus arrhythmia ratio and
cold pressor response remained abnormal. The dos-
es of phenylephrine and nitroprusside that changed
the systolic blood pressure by 25 mm Hg were 95 µg
and more than 1.0 µg per kilogram, respectively.
Both drugs elicited baroreflex-mediated changes in
the heart rate. The baroreflex sensitivity had in-
creased to 6 msec per millimeter of mercury. Saliva
production had increased by a factor of four (1.1 g
within five minutes). Minimal burst activity was re-
corded at the peroneal nerve (data not shown).
Four weeks after the first course of plasma ex-
 
Figure 2. Concentrations of Nicotinic Acetylcholine Receptor Antibody (Panel A) and Changes in Systolic Blood Pressure 
after One Minute of Standing (Panel B).
 
Over a period of 12 months, the patient underwent four courses of plasma exchange (shaded areas). Dotted lines indi-
cate normal values. 
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change, the patient’s symptoms gradually recurred.
The patient underwent a second course with similar-
ly good clinical and serologic responses. After a sec-
ond relapse, we started immunosuppressive thera-
py with prednisolone (at a dose of 60 mg per day)
and azathioprine (100 mg per day) and performed
two more courses of plasma exchange. The clinical
improvement with plasma exchange lasted eight
months before a fourth course became necessary.
Our patient’s history was remarkable for the pro-
gressive worsening of his symptoms over a period
of more than 20 years. The type and severity of the
autonomic deficits were typical of autoimmune au-
tonomic neuropathy and affected both sympathetic
and parasympathetic functions.
Signal transmission between the first and sec-
ond neuron in both the sympathetic and parasym-
pathetic branches relies on the same nicotinic ace-
tylcholine receptors. The ganglionic acetylcholine
receptor is a pentameric transmembrane complex
usually consisting of two acetylcholine receptor sub-
units in combination with three acetylcholine recep-
tor beta subunits. This acetylcholine receptor is a
ligand-gated ion channel that mediates fast synap-
tic transmission in all peripheral autonomic gan-
glia. It is genetically and immunologically distinct
from the acetylcholine receptor at the neuromus-
cular junction, which consists of two acetylcho-
line receptor alpha-1 subunits in combination with
beta-1, delta, and epsilon subunits. 
These differences explain why autonomic dys-
function is rare among patients with myasthenia
gravis,
 
14
 
 and conversely, why our patient did not
have skeletal-muscle weakness. Studies in animals
showed that anti–ganglionic acetylcholine receptor
antibodies can interrupt sympathetic and parasym-
pathetic traffic, essentially acting as endogenous
discussion
 
Figure 3. Beat-to-Beat Recordings of Blood Pressure and Heart Rate When the Patient Was Supine and Standing 
before Plasma Exchange (Panel A) and One Week Afterward (Panel B).
 
Before plasma exchange, the blood pressure decreased profoundly when the patient was standing, without a compensa-
tory increase in heart rate (beats per minute [bpm]). After 30 seconds, the patient had to sit because of presyncopal 
symptoms. After plasma exchange, the blood pressure decreased only mildly after standing and the heart rate increased 
adequately. The patient was able to stand for more than 15 minutes without symptoms. Shading indicates when the pa-
tient was standing.
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ganglionic blockers.
 
15,16
 
 In our patient, the antibod-
ies inhibited cholinergic responses in cells express-
ing ganglionic acetylcholine receptors. An antibody
that acts as an endogenous ganglionic blocker
should reproduce physiological changes identical
with those of pharmacologic ganglionic blockade.
The orthostatic hypotension, decreased gastroin-
testinal motility, tonic pupils, and reduced plasma
norepinephrine levels in our patient are typical ef-
fects of pharmacologic ganglionic blockade.
 
17,18
 
The response in our patient to large-volume
plasma exchanges supports the notion that primary
autoimmune autonomic failure is directly caused
by anti–ganglionic acetylcholine receptor antibod-
ies and that the immunologic ganglionic blockade
is potentially reversible. Plasma exchange improved
both sympathetic and parasympathetic responses.
In particular, upright blood pressure was better
maintained and the patient’s ability to stand in-
creased dramatically. The improvement in ortho-
static blood pressure and heart-rate regulation
correlated with the decrease in the levels of anti–
ganglionic acetylcholine receptor antibodies. Before
plasma exchange, the patient was highly sensitive
to pharmacologically induced changes in blood
pressure with phenylephrine or sodium nitroprus-
side. Removal of the antibodies attenuated this sen-
sitivity and was accompanied by improved barore-
flex regulation of the heart rate. The response in
our patient to plasma exchange supports the idea
that he was indeed a “hexamethonium man.” Gan-
glionic blockade by ganglionic anti–ganglionic ace-
tylcholine receptor antibodies should be recognized
as a cause of severe autonomic failure, and patients
with autonomic failure that is not otherwise ex-
plained should be tested for presence of anti–gan-
glionic acetylcholine receptor antibodies.
 
Supported by grants from Deutsche Forschungsgemeinschaft (to
Drs. Jordan, Kettritz, and Luft), Bundesministerium für Bildung
und Forschung (to Drs. Jordan, Tank, Kettritz, and Luft), and Helm-
holtz Stiftung (to Dr. Luft) and by grants from Abbott, Novartis, and
Sanofi-Aventis (to Dr. Jordan).
Dr. Jordan reports having received lecture fees from Abbott and
Sanofi-Aventis.
 
references
 
1.
 
Paton WD. Transmission and block in
autonomic ganglia. Pharmacol Rev 1954;6:
59-67.
 
2.
 
Heafield MT, Gammage MD, Nightin-
gale S, Williams AC. Idiopathic dysautono-
mia treated with intravenous gammaglobu-
lin. Lancet 1996;347:28-9.
 
3.
 
Smit AA, Vermeulen M, Koelman JH,
Wieling W. Unusual recovery from acute pa-
nautonomic neuropathy after immunoglob-
ulin therapy. Mayo Clin Proc 1997;72:333-5. 
 
4.
 
Venkataraman S, Alexander M, Gnana-
muthu C. Postinfectious pandysautonomia
with complete recovery after intravenous
immunoglobulin therapy. Neurology 1998;
51:1764-5.
 
5.
 
Mericle RA, Triggs WJ. Treatment of
acute pandysautonomia with intravenous
immunoglobulin. J Neurol Neurosurg Psy-
chiatry 1997;62:529-31.
 
6.
 
Dalakas MC. The use of intravenous
immunoglobulin in the treatment of auto-
immune neuromuscular diseases: evidence-
based indications and safety profile. Phar-
macol Ther 2004;102:177-93.
 
7.
 
Vernino S, Adamski J, Kryzer TJ, Fealey
RD, Lennon VA. Neuronal nicotinic ACh re-
ceptor antibody in subacute autonomic neu-
ropathy and cancer-related syndromes.
Neurology 1998;50:1806-13.
 
8.
 
Lennon VA, Ermilov LG, Szurszewski
JH, Vernino S. Immunization with neuronal
nicotinic acetylcholine receptor induces
neurological autoimmune disease. J Clin In-
vest 2003;111:907-13.
 
9.
 
Vernino S, Low PA, Fealey RD, Stewart
JD, Farrugia G, Lennon VA. Autoantibodies
to ganglionic acetylcholine receptors in au-
toimmune autonomic neuropathies. N Engl
J Med 2000;343:847-55.
 
10.
 
Low PA. Testing the autonomic nervous
system. Semin Neurol 2003;23:407-21.
 
11.
 
Tank J, Schroeder C, Diedrich A, et al.
Selective impairment in sympathetic vaso-
motor control with norepinephrine trans-
porter inhibition. Circulation 2003;107:
2949-54.
 
12.
 
Shannon JR, Jordan J, Black BK, Costa F,
Robertson D. Uncoupling of the baroreflex
by N(N)-cholinergic blockade in dissecting
the components of cardiovascular regula-
tion. Hypertension 1998;32:101-7.
 
13.
 
Klein CM, Vernino S, Lennon VA, et al.
The spectrum of autoimmune autonomic
neuropathies. Ann Neurol 2003;53:752-8.
 
14.
 
Vernino S, Cheshire WP, Lennon VA.
Myasthenia gravis with autoimmune auto-
nomic neuropathy. Auton Neurosci 2001;
88:187-92.
 
15.
 
Vernino S, Low PA, Lennon VA. Experi-
mental autoimmune autonomic neuropa-
thy. J Neurophysiol 2003;90:2053-9.
 
16.
 
Vernino S. Ermilov LG, Sha L, Szur-
szewski JH, Low PA, Lennon VA. Passive
transfer of autoimmune autonomic neurop-
athy to mice. J Neurosci 2004;24:7037-42.
 
17.
 
Goldstein DS, Zimlichman R, Stull R,
Keiser HR, Kopin IJ. Estimation of intrasyn-
aptic norepinephrine concentrations in hu-
mans. Hypertension 1986;8:471-5.
 
18.
 
Jordan J, Shannon JR, Black BK, et al.
N(N)-nicotinic blockade as an acute human
model of autonomic failure. Hypertension
1998;31:1178-84.
 
Copyright © 2005 Massachusetts Medical Society.
The New England Journal of Medicine 
Downloaded from nejm.org at MAX DELBRUECK CENTRUM FOR MOLECULAR MED on April 2, 2014. For personal use only. No other uses without permission. 
 Copyright © 2005 Massachusetts Medical Society. All rights reserved. 
